IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Scheller, D. et al.

Serial No.:

10/565,699

Filed:

January 25, 2006

Title:

USE OF ROTIGOTINE FOR THE TREATMENT OF

DEPRESSION

Group Art Unit:

1617

Examiner:

Carter, Kendra D.

Confirmation No.: 2513

Docket No.:

6102-000009/US/NP

Client Ref.:

P/Sche/11/4/03

SUBMITTED ELECTRONICALLY VIA EFS-WEB

6 October 2009

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

PRELIMINARY AMENDMENT (AMENDMENT C) SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Prior to examination on the merits, please enter the following amendment, which is further to Amendment B filed on 15 March 2007. Applicant does not believe any fee is owed to submit the Preliminary Amendment. However, authorization is provided herewith to charge any such fee that may be required to Deposit Account No. 08-0750.

Applicant also submits a Supplemental Information Disclosure Statement (IDS) under 37 C.F.R. §1.97(b)(3).

Amendment in the SPECIFICATION begins on page 2 of this paper.

Remarks on the present amendment begin on page 3 of this paper.